Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection | Zendy

Ira M. Jacobson | Zendy; John G. McHutchison | Zendy; Geoffrey Dusheiko | Zendy; Adrian M. Di Bisceglie | Zendy; K. Rajender Reddy | Zendy; Natalie Bzowej | Zendy; Patrick Marcellin | Zendy; Andrew J. Muir | Zendy; Péter Ferenci | Zendy; Robert Flisiak | Zendy; Jacob George | Zendy; Mario Rizzetto | Zendy; Daniel Shouval | Zendy; Ricard Solà | Zendy; Rubén Terg | Zendy; Eric M. Yoshida | Zendy; Nathalie Adda | Zendy; Leif Bengtsson | Zendy; Abdul J. Sankoh | Zendy; Tara L. Kieffer | Zendy; Shelley George | Zendy; Robert S. Kauffman | Zendy; Stefan Zeuzem | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

Author(s) -

Ira M. Jacobson,

John G. McHutchison,

Geoffrey Dusheiko,

Adrian M. Di Bisceglie,

K. Rajender Reddy,

Natalie Bzowej,

Patrick Marcellin,

Andrew J. Muir,

Péter Ferenci,

Robert Flisiak,

Jacob George,

Mario Rizzetto,

Daniel Shouval,

Ricard Solà,

Rubén Terg,

Eric M. Yoshida,

Nathalie Adda,

Leif Bengtsson,

Abdul J. Sankoh,

Tara L. Kieffer,

Shelley George,

Robert S. Kauffman,

Stefan Zeuzem

Publication year - 2011

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1012912

Subject(s) - ribavirin , telaprevir , medicine , gastroenterology , placebo , hepatitis c virus , peginterferon alfa 2a , virology , hepatitis c , virus , pathology , alternative medicine

In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease inhibitor, in combination with peginterferon-ribavirin, as compared with peginterferon-ribavirin alone, has shown improved efficacy, with potential for shortening the duration of treatment in a majority of patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research